American Academy of Neurology annual meeting – April 17-22, 2021
Wednesday, April 21 edition
Tuesday, April 20 edition
CONGRESS HIGHLIGHTS – MONDAY EDITION Read More
Latest News
AAN 2021 Poster Picks – Day 1
April 19, 2021AAN 2021 Poster Picks – Day 3
AAN 2021 Poster Picks – Day 2
Poster 033 – Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
Kottil W. Rammohan, MD
Objective: 9-hole peg test (9-HPT) and 25-foot walk (25-FW) function. Read More
COVID vaccination: is one dose better than nothing?
April 13, 2021The government of Canada has opted to prolong the second COVID-19 vaccination to 16 weeks after the first dose due to a limited vaccine supply. The decision was based on a recommendation from the National Advisory Committee on Immunization (NACI; www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html#b1). The rationale is that administering one dose to a wider population will have a greater impact on severe COVID outcomes than giving the required two doses to fewer people. This raises the question: what are the benefits and risks of this partial-immunity approach? Read More
Early, effective MS treatment revisited
April 8, 2021The trend to the early use of higher-efficacy disease-modifying therapies (DMT) in the management of MS was put on pause during the pandemic due to concerns about the effects of these agents on the immune response to SARS-CoV-2 and, latterly, to COVID-19 vaccination. However, as the pandemic dragged on, it became impractical to interrupt or delay treatment, and current DMT recommendations now emphasize that the risks of undertreated MS outweigh the possible risks of COVID, especially in a younger population. Read More